Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is
better for preventing death and stroke in patients with poor heart function.
We are now transitioning into the sub-analysis part of the WARCEF patient data.
The study has recently completed data analysis for its Primary Aim. All randomized patients
have completed their follow up. All study related procedure as per the protocol has been
completed. We are now in the extension phase of the study to obtain more patient data to
address further aims of the study. No new procedures are performed and data already in place
at the sites will be collected (EKG and echocardiograms).
The aims for this study extension are:
- To assess progression of cardiac dysfunction over time among heart failure patients
- To correlate prognosis with cardiac dysfunction
Phase:
Phase 3
Details
Lead Sponsor:
Columbia University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)